Dexmedetomidina

Dexmedetomidina: nuevas vías Dexmedetomidine: New avenues. Department of Anesthesiology, Dayanand Medical College and Hospital, Ludhiana, Punjab, India J Anaesthesiol Clin Pharmacol. 2011 Jul;27(3):297-302. Alpha (α)-2-Adrenergic receptor (AR) agonists have been the focus of interest for their sedative, analgesic, perioperative sympatholytic, anesthetic-sparing, and hemodynamic-stabilizing properties. Dexmedetomidine, a highly selective a2-AR agonist with a relatively high ratio of α2/ α 1-activity (1620:1 as compared to 220:1 for clonidine), possesses all these properties but lacks respiratory depression, making it a useful and safe adjunct in diverse clinical applications. Numerous investigations into its uses have featured in various issues of this journal. This editorial aims to provide an overview of its current clinical status and new therapeutic avenues under investigation. http://joacp.org/article.asp?issn=0970-9185;year=2011;volume=27;issue=3;spage=297;epage=302;aulast=Grewal  Dexmedetomidina en la unidad de cuidado intensivo neurológico. Dexmedetomidine in the neurointensive care unit. Farag E. Department of Anesthesiology, Cleveland Clinic, Cleveland, Ohio 44195, USA. farage@ccf.org Discov Med. 2010 Jan;9(44):42-5. Abstract Dexmedetomidine is a new alpha-2 agonist with high specificity to alpha-2 receptors. The aim of this review is to present the most recent topics regarding the advantages in using dexmedetomidine in clinical anesthesia and intensive care, while discussing the controversial issue of its harmful effect on cerebral blood flow. http://www.discoverymedicine.com/Ehab-Farag/2010/01/11/dexmedetomidine-in-the-neurointensive-care-unit/

Atentamente Anestesiología y Medicina del Dolor www.anestesia-dolor.org